VALNEVA SE

Campus Bio-Ouest | 6, Rue Alain Bombard

44800 Saint-Herblain,France

Valneva Announces Termination of 2013 Shareholder

Agreement

Saint Herblain (France), April 3, 2019- Valneva SE ("Valneva" or "the Company"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that the parties to the shareholder agreement executed on July 5, 20131have decided not to renew it. Therefore, this agreement is due to expire on July 4, 2019.

The agreement included provisions for the composition of the supervisory and management boards, share retention commitments, reciprocal rights of first refusal and an anti-dilution protection for Bpifrance Participations.

About Valneva SE

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva's portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT®indicated for the prevention of Japanese encephalitis and DUKORAL®indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 480 employees. More information is available at www.valneva.com.

Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine

Teresa Pinzolits

Global Head of Investor Relations &

Corporate Communications Specialist

Corporate Communications

T +43 (0)1 20620 1116

M +33 (0)6 4516 7099

communications@valneva.com

investors@valneva.com

1Groupe Grimaud La Corbière, Bpifrance Participations and the founding management

Attachments

  • Original document
  • Permalink

Disclaimer

Valneva SE published this content on 03 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 April 2019 20:56:04 UTC